Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IGC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIGC Pharma extends $12M credit facility with O-Bank, facility fee rises 25%
Filed June 8, 2026 · Period ending June 5, 2026 · ~1 min read
Key Changes
-
medium
IGC extended its $12 million credit facility with Taiwan-based O-Bank for another year. The facility fee increased from $48,000 to $60,000 (up 25%), while all other material terms remain unchanged from the 2025 agreement.
Item 1.01 verify on EDGAR → -
medium
The extension creates a direct financial obligation for the company, maintaining IGC's access to working capital through its Taiwan banking relationship established in June 2025.
Item 2.03 verify on EDGAR →
Summary
IGC Pharma renewed its banking relationship with Taiwan's O-Bank, extending a credit facility that provides up to $12 million in borrowing capacity. The one-year extension keeps the company's financing structure intact with minimal changes—only the annual facility fee increased by $12,000 to $60,000. For retail investors, this is a routine refinancing event that signals continued access to working capital.
The 25% fee increase is modest in dollar terms but worth monitoring: if future renewals show accelerating costs or reduced credit limits, it could indicate tightening credit conditions or deteriorating creditworthiness. The key follow-on question is whether IGC actually draws on this facility in coming quarters, which would appear in future balance sheet filings and indicate the company's cash position and capital needs.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter (collectively, the “Loan Agreement”) with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as lender (the “Lender”).
IGC extended its existing credit facility with O-Bank, a Taiwan-based lender. The amendment extends the Master Loan and Security Agreement and General Banking Facility Letter that were originally established in June 2025.
Event · Item 2.03 — Creation of a Direct Financial Obligation
IGC Pharma disclosed creation of a direct financial obligation, with details incorporated by reference from Item 1.01.
Added in current filing · verify on EDGAR →
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 is incorporated herein by reference.
The company disclosed the creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03. The specific terms and details of this obligation are referenced in Item 1.01 of the filing, which is not included in the provided excerpt. This indicates the company has entered into a new debt arrangement, credit facility, or similar financial commitment.
Event · Item 9.01 — Financial Statements and Exhibits
IGC Pharma filed exhibits for 2026 and 2025 O-Bank general banking facility letters with no material business impact disclosed.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
2026 O-Bank General Banking Facility Letter.
The company filed a new 2026 general banking facility letter with O-Bank as Exhibit 10.1. The 8-K provides no details about the facility terms, size, or material changes from prior arrangements. Certain schedules or attachments were omitted per Regulation S-K but will be furnished to the SEC upon request.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify